title: The cultivable human oral gluten-degrading microbiome and its potential implications in coeliac disease and gluten sensitivity.
abstract: Coeliac disease is characterized by intestinal inflammation caused by gluten, proteins which are widely contained in the Western diet. Mammalian digestive enzymes are only partly capable of cleaving gluten, and fragments remain that induce toxic responses in patients with coeliac disease. We found that the oral microbiome is a novel and rich source of gluten-degrading organisms. Here we report on the isolation and characterization of the cultivable resident oral microbes that are capable of cleaving gluten, with special emphasis on the immunogenic domains. Bacteria were obtained by a selective culturing approach and enzyme activities were characterized by: (i) hydrolysis of paranitroanilide-derivatized gliadin-derived tripeptide substrates; (ii) gliadin degradation in-gel (gliadin zymography); (iii) gliadin degradation in solution; (iv) proteolysis of the highly immunogenic α-gliadin-derived 33-mer peptide. For selected strains pH activity profiles were determined. The culturing strategy yielded 87 aerobic and 63 anaerobic strains. Species with activity in at least two of the four assays were typed as: Rothia mucilaginosa HOT-681, Rothia aeria HOT-188, Actinomyces odontolyticus HOT-701, Streptococcus mitis HOT-677, Streptococcus sp. HOT-071, Neisseria mucosa HOT-682 and Capnocytophaga sputigena HOT-775, with Rothia species being active in all four assays. Cleavage specificities and substrate preferences differed among the strains identified. The approximate molecular weights of the enzymes were ~75 kD (Rothia spp.), ~60 kD (A. odontolyticus) and ~150 kD (Streptococcus spp.). In conclusion, this study identified new gluten-degrading microorganisms in the upper gastrointestinal tract. A cocktail of the most active oral bacteria, or their isolated enzymes, may offer promising new treatment modalities for coeliac disease.
authors.affiliation: Department of Periodontology and Oral Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA 02118, USA.
authors.forename: M
authors.initials: M
authors.lastname: Fernandez-Feo
authors.forename: G
authors.initials: G
authors.lastname: Wei
authors.forename: G
authors.initials: G
authors.lastname: Blumenkranz
authors.forename: F E
authors.initials: FE
authors.lastname: Dewhirst
authors.forename: D
authors.initials: D
authors.lastname: Schuppan
authors.forename: F G
authors.initials: FG
authors.lastname: Oppenheim
authors.forename: E J
authors.initials: EJ
authors.lastname: Helmerhorst
mesh_terms: D000190:Actinomyces / Q000201:enzymology / Q000302:isolation & purification; D001419:Bacteria / Q000201:enzymology* / Q000302:isolation & purification*; D002206:Capnocytophaga / Q000201:enzymology / Q000302:isolation & purification; D002446:Celiac Disease / Q000188:drug therapy / Q000201:enzymology; D003773:Dental Plaque / Q000382:microbiology*; D005903:Gliadin / Q000737:chemistry / Q000378:metabolism*; D005983:Glutens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D064307:Microbiota; D042807:Neisseria mucosa / Q000201:enzymology / Q000302:isolation & purification; D012463:Saliva / Q000382:microbiology*; D013291:Streptococcus / Q000201:enzymology / Q000302:isolation & purification
chemical_list: D005983:Glutens; D005903:Gliadin
keywords: Coeliac disease; degradation; gliadin; oral bacteria; proteases